3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
4
Gastrointestinal
2
Thoracic
1
Genitourinary
1
Breast
1
Conditions
Colorectal Neoplasms
1422
Pancreatic Neoplasms
847
Carcinoma, Hepatocellular
736
Stomach Neoplasms
639
Colonic Neoplasms
441
Rectal Neoplasms
400
Esophageal Neoplasms
395
Carcinoma, Non-Small-Cell Lung
328
Breast Neoplasms
328
Neoplasms
300
Liver Neoplasms
280
Cholangiocarcinoma
242
Ovarian Neoplasms
240
Lung Neoplasms
238
Neoplasm Metastasis
237
Gastrointestinal Neoplasms
216
Melanoma
184
Prostatic Neoplasms
162
Esophageal Squamous Cell Carcinoma
160
Biliary Tract Neoplasms
160
Endometrial Neoplasms
141
Squamous Cell Carcinoma of Head and Neck
128
Uterine Cervical Neoplasms
127
Carcinoma, Renal Cell
113
Head and Neck Neoplasms
112
Sarcoma
100
Urinary Bladder Neoplasms
95
Adenocarcinoma Of Esophagus
89
Triple Negative Breast Neoplasms
84
Anus Neoplasms
83
Interventions
tazemetostat
1
durvalumab
1
brigimadlin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Tertiary Lymphoid Structures
×
Gastrointestinal
×
1 year
×
Clear all
NCT04705818
2026-03-06
CAIRE
Institut Bergonié
Phase 2
Completed
164 enrolled
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn